Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Human Gene Therapy

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/hum.2008.107PMID 18774912PMCID PMC2940541
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of Choroidal Neovascularization via Brief Subretinal Exposure to a Newly Developed Lentiviral Vector Pseudotyped with Sendai Viral Envelope Proteins

  2010cited by this paper
• The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques.

  2010cited by this paper
• Progress and prospects: immune responses to viral vectors

  2010cited by this paper
• A novel day blindness in sheep: epidemiological, behavioural, electrophysiological and histopathological studies.

  2010cited by this paper
• Channelrhodopsins provide a breakthrough insight into strategies for curing blindness

  2009cited by this paper
• Gene therapy for diseases of the cornea – a review

  2009cited by this paper
• Strategies to modulate immune responses: a new frontier for gene therapy.

  2009cited by this paper
• Integration-deficient lentiviral vectors: a slow coming of age.

  2009cited by this paper
• An experimental platform for systemic drug delivery to the retina

  2009cited by this paper
• Acute Toxicity Study of a Simian Immunodeficiency Virus-Based Lentiviral Vector for Retinal Gene Transfer in Nonhuman Primates

  2009cited by this paper
• Pharmacological Activation of Guanine Nucleotide Exchange Factors for the Small GTPase Rap1 Recruits High-Affinity β1 Integrins as Coreceptors for Parvovirus B19: Improved Ex Vivo Gene Transfer to Human Erythroid Progenitor Cells

  2009cited by this paper
• Implants for artificial vision

  2009cited by this paper
• Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1

  2009cited by this paper
• Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy.

  2009cited by this paper
• Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous.

  2009cited by this paper
• Human RPE65 Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year

  2009cited by this paper
• Adeno-associated virus capsid serotype identification: Analytical methods development and application.

  2009cited by this paper
• Leber congenital amaurosis: clinical correlations with genotypes, gene therapy trials update, and future directions.

  2009cited by this paper
• A History Lesson for Stem Cells

  2009cited by this paper
• Progress toward effective treatments for human photoreceptor degenerations.

  2009cited by this paper
• Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

  2009cited by this paper
• Fostering translation of genetics research: an NIDDK perspective.

  2009cited by this paper
• Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST)

  2009cited by this paper
• Vision 1 year after gene therapy for Leber's congenital amaurosis.

  2009cited by this paper
• Retinal laminar architecture in human retinitis pigmentosa caused by Rhodopsin gene mutations.

  2008cited by this paper
• Immunity to adeno-associated virus vectors in animals and humans: a continued challenge

  2008cited by this paper
• Preliminary results of gene therapy for retinal degeneration.

  2008influential reference
• Effect of gene therapy on visual function in Leber's congenital amaurosis.

  2008influential reference
• Safety and efficacy of gene transfer for Leber's congenital amaurosis.

  2008cited by this paper
• Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer.

  2008cited by this paper
• Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations.

  2008cited by this paper
• Canine and Human Visual Cortex Intact and Responsive Despite Early Retinal Blindness from RPE65 Mutation

  2007cited by this paper
• Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents.

  2007cited by this paper
• Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials

  2007cited by this paper
• Electroretinographic analyses of Rpe65-mutant rd12 mice: developing an in vivo bioassay for human gene therapy trials of Leber congenital amaurosis.

  2007cited by this paper
• Evaluation of Cellular Immune Responses in Subjects Chronically Infected with HIV Type 1

  2007cited by this paper
• Human cone photoreceptor dependence on RPE65 isomerase

  2007cited by this paper
• Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Serotype 2 α1-Antitrypsin (AAT) Vector in AAT-Deficient Adults

  2006cited by this paper
• Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection.

  2006cited by this paper
• Safety in Nonhuman Primates of Ocular AAV2-RPE65, a Candidate Treatment for Blindness in Leber Congenital Amaurosis

  2006cited by this paper
• Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations.

  2006cited by this paper
• Two Point Mutations of RPE65 from Patients with Retinal Dystrophies Decrease the Stability of RPE65 Protein and Abolish Its Isomerohydrolase Activity*

  2006cited by this paper
• Ultrahigh-resolution optical coherence tomography in patients with decreased visual acuity after retinal detachment repair.

  2006cited by this paper
• Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants.

  2006cited by this paper
• The correlation between height of macular detachment and visual outcome in macula-off retinal detachments of < or = 7 days' duration.

  2005cited by this paper
• Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.

  2005cited by this paper
• Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle.

  2005cited by this paper
• Identification of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile retinitis pigmentosa

  2005cited by this paper
• Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success

  2005cited by this paper
• Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures.

  2005cited by this paper
• Anatomy and development of the macula: specialisation and the vulnerability to macular degeneration

  2005cited by this paper
• Laser flare-cell photometry: methodology and clinical applications.

  2005cited by this paper
• Adeno-associated viral vectors for clinical gene transfer studies.

  2005cited by this paper
• The association between visual acuity and central retinal thickness in retinitis pigmentosa.

  2005influential reference
• Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA).

  2005cited by this paper
• Gene therapy of retinal dystrophies: achievements, challenges and prospects.

  2004cited by this paper
• In utero gene therapy rescues vision in a murine model of congenital blindness.

  2004cited by this paper
• Management of macular holes that develop after retinal detachment repair.

  2003cited by this paper
• Ocular immune privilege: therapeutic opportunities from an experiment of nature

  2003cited by this paper
• A Tyr368His RPE65 founder mutation is associated with variable expression and progression of early onset retinal dystrophy in 10 families of a genetically isolated population

  2003cited by this paper
• Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors.

  2002cited by this paper
• Production of clinical-grade recombinant adeno-associated virus vectors.

  2002cited by this paper
• Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects.

  2002cited by this paper
• Clinical course and visual function in a family with mutations in the RPE65 gene.

  2002cited by this paper
• Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors

  2001cited by this paper
• Gene therapy restores vision in a canine model of childhood blindness

  2001cited by this paper
• Four novel mutations in the RPE65 gene in patients with Leber congenital amaurosis

  2001cited by this paper
• Early-onset severe rod-cone dystrophy in young children with RPE65 mutations.

  2000cited by this paper
• Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration.

  2000cited by this paper
• Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model

  1999influential reference
• Histopathology of the human retina in retinitis pigmentosa.

  1998cited by this paper
• Relation of optical coherence tomography to microanatomy in normal and rd chickens.

  1998cited by this paper
• Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors

  1998cited by this paper
• Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis.

  1998influential reference
• Visual recovery in macula-off rhegmatogenous retinal detachments.

  1998cited by this paper
• Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle

  1998cited by this paper
• Standardization of vitreal inflammatory activity in intermediate and posterior uveitis.

  1985cited by this paper
• New visual acuity charts for clinical research.

  1982cited by this paper
• Recovery of visual acuity after retinal detachment involving the macula.

  1982cited by this paper
• Signs and symptoms of uveitis. I. Anterior uveitis.

  1959cited by this paper

• Ocular gene therapy mediated by AAV vectors: an overview of immunosuppressive treatments and immunomonitoring of patients involved in clinical trials.

  2026cites this paper
• Inter-individual variability in immune response to AAV ocular gene delivery across species impedes immunomonitoring.

  2026cites this paper
• mGem: AAV, from almost a virus to an awesome vector—or is it?

  2026cites this paper
• Combination gene therapy with AAV based RPE65 and survivin vectors sustains phenotypic rescue in neural retina of LCA2 mice.

  2026cites this paper
• Diagnostic Role of Chromatic Full-Field Stimulus Test in Rod-Cone Versus Cone Dystrophies.

  2026cites this paper
• Clinical and pharmacovigilance safety evaluation of LUXTURNA® (voretigene neparvovec-rzyl)

  2025cites this paper
• Addressing Challenges in Developing Treatments for Inherited Retinal Diseases: Recommendations From the Third Monaciano Symposium

  2025cites this paper
• Test–retest variability of the full‐field stimulus test in patients with retinitis pigmentosa: REPEAT Study Report No. 4

  2025cites this paper
• Lipid nanoparticle mediated base editing of the Q344X rhodopsin mutation associated with retinitis pigmentosa.

  2025cites this paper
• The advancements in precision medicine for Leber congenital amaurosis: Breakthroughs from genetic diagnosis to therapy.

  2025cites this paper
• Chromatography in Downstream Processing of Recombinant Adeno‐Associated Viruses: A Review of Current and Future Practises

  2025cites this paper
• Measuring historical variant reclassification in inherited retinal disease and its impact on clinical genetic testing

  2025cites this paper
• Recovery of cone-mediated vision in Lebercilin associated retinal ciliopathy after gene therapy: One-year results of a phase I/II trial

  2025cites this paper
• Gene Therapy Strategies for the Treatment of Bestrophinopathies

  2025cites this paper
• Dogs help tease apart important differences in gene expression of brain tumours

  2025cites this paper
• The role of microRNAs in the pathophysiology of the aging eye.

  2025cites this paper
• Exploring the potential for gene therapy in Cav1.4-related retinal channelopathies

  2025cites this paper
• The role of full-field stimulus threshold in evaluating Bietti crystalline dystrophy.

  2025cites this paper
• Visual Neurorestoration: An Expert Review of Current Strategies for Restoring Vision in Humans

  2025cites this paper
• Precision gene therapy: Tailoring rAAV-mediated gene therapies for inherited retinal dystrophies (IRDs).

  2025cites this paper
• Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy.

  2025cites this paper
• Preclinical Assessment of Mitochondrial-Targeted ND4 Gene Therapy for Leber Hereditary Optic Neuropathy

  2025cites this paper
• "Seeing Stars": The Gene Therapy Revolution.

  2025cites this paper
• A Comprehensive Review of Clinically Applied Adeno-Associated Virus-Based Gene Therapies for Ocular Disease

  2025cites this paper
• Gene and Stem Cell-Based Therapies for Retinal Degenerative Diseases: Update, Challenges, and Future Directions

  2025cites this paper
• Location and Identity of Photoreceptors Contributing to the Full-Field Stimulus Test (FST)

  2025cites this paper
• Therapeutic potential of allogeneic iPS cell-derived RPE transplantation for RPE65-LCA

  2025cites this paper
• The Versatile Roles of Retinal Pigment Epithelium in the Pathophysiology of Retinitis Pigmentosa.

  2025cites this paper
• Precision ophthalmology: a call for Africa not to be left in the dark

  2024cites this paper
• Partial rescue of the full-field electroretinogram in patients with RPE65-related retinal dystrophy following gene augmentation therapy with voretigene neparvovec-rzyl

  2024cites this paper
• Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno-associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation

  2024cites this paper
• Perimacular Atrophy Following Voretigene Neparvovec-Rzyl Treatment in the Setting of Previous Contralateral Eye Treatment With a Different Viral Vector

  2024cites this paper
• Recombinant Adeno-Associated Virus as a Delivery Platform for Ocular Gene Therapy: A Comprehensive Review.

  2024cites this paper
• Peripheral Cellular Immune Responses Induced by Subretinal Adeno-Associated Virus Gene Transfer Can Be Restrained by the Subretinal-Associated Immune Inhibition Mechanism

  2024cites this paper
• Relationship between the full‐field stimulus test and self‐reported visual function in patients with retinitis pigmentosa: REPEAT Study report No. 3

  2024cites this paper
• 12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy

  2024cites this paper
• Challenges in AAV-Based Retinal Gene Therapies and the Role of Magnetic Nanoparticle Platforms

  2024cites this paper
• Translational Research and Therapies for Neuroprotection and Regeneration of the Optic Nerve and Retina: A Narrative Review

  2024cites this paper
• Infantile Nystagmus Syndrome—Associated Inherited Retinal Diseases: Perspectives from Gene Therapy Clinical Trials

  2024cites this paper
• Gene therapy for retinal diseases: From genetics to treatment

  2024cites this paper
• Retinal Degeneration Associated With Biallelic RDH12 Variants: Longitudinal Evaluation of Retinal Structure and Visual Function in Pediatric Patients

  2024cites this paper
• Recent Advancements and Applications of Ophthalmic Gene Therapy Strategies: A Breakthrough in Ocular Therapeutics.

  2024cites this paper
• Efficient retinal ganglion cells transduction by retro-orbital venous sinus injection of AAV-PHP.eB in mature mice.

  2024cites this paper
• A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders

  2024cites this paper
• Understanding AAV vector immunogenicity: from particle to patient

  2024cites this paper
• Recent developments in gene therapy research in India

  2024cites this paper
• A New Generation of Gene Therapies as the Future of Wet AMD Treatment

  2024cites this paper
• Publication trends of Leber congenital amaurosis researches: a bibliometric study during 2002-2022.

  2024cites this paper
• Retinal Imaging Findings in Inherited Retinal Diseases

  2024cites this paper
• Update on gene therapies in pediatric ophthalmology.

  2023cites this paper
• AAV for Gene Therapy in Ocular Diseases: Progress and Prospects

  2023cites this paper
• Gene Therapy and Cardiovascular Diseases.

  2023cites this paper
• Bibliometric analysis of global research trends in adeno-associated virus vector for gene therapy (1991-2022)

  2023cites this paper
• AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies

  2023cites this paper
• Full-field stimulus threshold testing: a scoping review of current practice

  2023influential citation
• Steady-Hand Eye Robot 3.0: Optimization and Benchtop Evaluation for Subretinal Injection

  2023cites this paper
• Gene therapies in pediatric ophthalmology

  2023cites this paper
• Insights into adeno-associated virus-based ocular gene therapy: A bibliometric and visual analysis

  2023cites this paper
• THE JEREMIAH METZGER LECTURE: TURNING GENES INTO MEDICINES: HIGHLIGHTS AND HURDLES IN THE DEVELOPMENT OF GENE THERAPY FOR GENETIC DISEASE.

  2023cites this paper
• Recent advances and future prospects: current status and challenges of the intraocular injection of drugs for vitreoretinal diseases.

  2023cites this paper
• Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy

  2023cites this paper
• Safety and Efficacy of Adeno-Associated Viral Gene Therapy in Patients With Retinal Degeneration: A Systematic Review and Meta-Analysis

  2023influential citation
• Clinical applications of gene therapy for rare diseases: A review

  2023cites this paper
• Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration

  2023cites this paper
• Intravitreal Administration of AAV2-SIRT1 Reverses Diabetic Retinopathy in a Mouse Model of Type 2 Diabetes

  2023cites this paper
• Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy

  2023cites this paper
• CRISPRi-Mediated Treatment of Dominant Rhodopsin-Associated Retinitis Pigmentosa

  2023cites this paper
• Preclinical evaluation of ADVM-062, a novel intravitreal gene therapy vector for the treatment of blue cone monochromacy

  2023cites this paper
• MicroRNAs as potential biomarkers and therapeutic targets in age-related macular degeneration

  2023cites this paper
• In Vivo Efficacy and Safety Evaluations of Therapeutic Splicing Correction Using U1 snRNA in the Mouse Retina

  2023cites this paper
• Modulating the activity of human nociceptors with a SCN10A promoter-specific viral vector tool

  2023cites this paper
• Blue cone monochromacy and gene therapy.

  2023cites this paper
• Current Advances in Gene Therapies of Genetic Auditory Neuropathy Spectrum Disorder

  2023cites this paper
• Gene Therapy for Ophthalmic Diseases

  2023cites this paper
• Evaluation of Genetic Testing in a Cohort of Diverse Pediatric Patients in the United States with Congenital Cataracts

  2023cites this paper
• AAV6-Mediated Gene Therapy Prevents Developmental Dentin Defects in a Dentinogenesis Imperfecta Type Ⅲ Mouse Model

  2023cites this paper
• Adeno-associated virus mediated gene therapy for neuroprotection of retinal ganglion cells in glaucoma.

  2023cites this paper
• Viral Vectors in Gene Replacement Therapy

  2023cites this paper
• Gene-agnostic approaches to treating inherited retinal degenerations

  2023cites this paper
• Stem Cell and Gene Therapy for Inherited Retinal Diseases

  2022cites this paper
• Gene Therapy for Rare Neurological Disorders

  2022cites this paper
• A Modified Arrestin1 Increases Lactate Production in the Retina and Slows Retinal Degeneration

  2022cites this paper
• Computational Genomics in the Era of Precision Medicine: Applications to Variant Analysis and Gene Therapy

  2022cites this paper
• Delivery strategies for CRISPR/Cas genome editing tool for retinal dystrophies: challenges and opportunities

  2022cites this paper
• RPE based gene and cell therapy for inherited retinal diseases: A review.

  2022cites this paper
• Use of Avian Adeno-Associated Virus for the Delivery of Transgenes to Pekin Duck Cells in vitro and in vivo

  2022cites this paper
• Review of gene therapies for age-related macular degeneration

  2022cites this paper
• [Gene therapy treatment based on an ophthalmic indication in hereditary retinal dystrophy caused by RPE65 biallelic gene mutation.]

  2022cites this paper
• Employing nonhomologous end joining and homology-directed repair for treatment of Leber congenital amaurosis and inherited retinal degeneration

  2022cites this paper
• Genome Editing of Pik3cd Impedes Abnormal Retinal Angiogenesis

  2022cites this paper
• The use of melittin to enhance transgene expression mediated by recombinant adeno-associated virus serotype 2 vectors both in vitro and in vivo.

  2022cites this paper
• Non-Viral Delivery of CRISPR/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations

  2022cites this paper
• Injectable Hydrogel Based on Gellan Gum/Silk Sericin for Application as a Retinal Pigment Epithelium Cell Carrier

  2022cites this paper
• The use of canine models to develop translational gene therapies for the treatment of six forms of inherited retinal degenerations

  2022cites this paper
• Postnatal eye size in mice is controlled by SREBP2-mediated transcriptional repression of Lrp2 and Bmp2

  2022cites this paper
• [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia].

  2022cites this paper
• The protective effects of systemic dexamethasone on sensory epithelial damage and hearing loss in targeted Cx26-null mice

  2022cites this paper
• Mobility test to assess functional vision in dark-adapted patients with Leber congenital amaurosis

  2022cites this paper
• Postnatal eye size in mice is controlled by SREBP2-mediated transcriptional repression of Lrp2 and Bmp2.

  2022cites this paper
• OPTH_A_364200 1753..1771

  2022cites this paper